Fluoxetine therapy in Multiple Sclerosis. A double blind, randomised, placebo-controlled, phase II study in patients with relapsing Multiple Sclerosis.
Completed
- Conditions
- Relapsing multiple sclerosis.
- Registration Number
- NL-OMON23750
- Lead Sponsor
- Multiple Sclerosis Internationaal, Amsterdam, The Netherlands
- Brief Summary
J Neurol Neurosurg Psychiatry. 2008 Sep;79(9):1027-31. Epub 2008 May 1.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1. Written informed consent;
2. Male and female patients aged 18 to 65 years inclusive;
Exclusion Criteria
1. Intolerance or contraindications to MRI scanning;
2. Abnormal MRI scan, not attributable to MS;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method